Skip to content

SAMHD1 Research Digest — 2026-08-05

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 9 papers evaluated | 3 high-relevance (≥7) | 3 medium (5–6) | 3 low (3–4) | 0 scored <3

🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Circadian rhythm disruption induces cardiac hypertrophy via promoting the mtDNA release-activated cGAS-STING pathway. (from Cardiology)
Ouyang Zizhang; Luo Runqi; Li Jingxuan; Huang Qiuyan; Chen Ziying — 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, clinical-phenotype

Demonstrates mtDNA release-driven cGAS-STING activation causing cardiac hypertrophy, directly relevant to Loop A mechanism and the family's cardiac/mitochondrial-interferonopathy phenotype spectrum.
DOI: 10.1016/j.bcp.2026.118309

ATP6AP2 ameliorates inflammation and pyroptosis in heart failure by promoting lysosome-dependent STING degradation. (from Cardiology)
Zhao Xuan; Zhang Hui; Ding Xinyue; Wu Huimin; Li Min — Apoptosis : an international journal on programmed cell death 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, NLRP3, mTOR-lysosomal

Demonstrates lysosome-mediated STING degradation regulating STING-TBK1-IRF3 signaling and downstream pyroptosis/inflammation in a cardiac model, directly relevant to the BLUE loop's cGAS-STING axis and cardiac interferonopathy phenotype relevant to family cardiology risk.
DOI: 10.1007/s10495-026-02415-x

JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients. (from Pediatric rheumatology/autoinflammatory disease)
Vahabi Seyed Mohammad; Pourgholi Elnaz; Leblebici Can Berk; Crisler William J; H — European journal of pediatrics 2026
Score: 7/10 | Pathways: JAK-STAT, AGS-spectrum, treatment-target

CANDLE is a proteasome-associated type I interferonopathy successfully treated with JAK inhibitors (baricitinib/tofacitinib), directly supporting the JAK-STAT axis and JAK-inhibitor therapeutic strategy relevant to SAMHD1-driven interferonopathy.
DOI: 10.1007/s00431-026-07293-8

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling (from Oncology/hematology)
Huan Chen; N. An; Linlin Yang; Jin Lou; Yuming Pan — Extracellular Vesicles and Circulating Nucleic Acids 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, gene-therapy-delivery

Demonstrates mtDNA leakage-driven cGAS-STING-IFN-I activation via a TFAM-mitochondrial genome instability axis analogous to the BLUE pathway, plus EV-siRNA delivery relevant to future targeted therapeutics, though in an oncology (AML) rather than SAMHD1 context.
DOI: 10.20517/evcna.2026.36

Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways. (from Nephrology/Cardiology pharmacology (natural compound therapeutics for hyperuricemia-induced organ damage))
Li Yongmei; Xu Yuexin; Ye Wenjie; Yu Zeqi; Wu Zhenkun — Journal of biochemical and molecular toxicology 2026
Score: 6/10 | Pathways: urate-NLRP3, NF-kB-NLRP3-priming, NLRP3, treatment-target

This paper demonstrates that uric acid drives NF-κB/NLRP3 inflammasome activation causing renal and cardiac injury, directly modeling the GOLD pathway (dGTP→purine catabolism→uric acid→NLRP3) and NF-κB-NLRP3 priming crosstalk relevant to SAMHD1-driven interferonopathy, though it lacks any SAMHD1 or interferon-specific mechanism.
DOI: 10.1002/jbt.71058

Advancements in Diagnosis and Care for Immune Dysregulation and Inborn Errors of Immunity in Pediatric Rheumatology - Our 50-year Journey. (from Pediatric rheumatology)
M. Day-Lewis; Jennifer L Cheng; Edward M. Behrens; Melissa M Hazen; E. Janssen — Arthritis care & research 2026
Score: 5/10 | Pathways: cGAS-STING, NLRP3, JAK-STAT, AGS-spectrum, treatment-target, clinical-phenotype

General review of pediatric rheumatology's role in interferonopathies and inflammasome-driven disease provides relevant clinical/therapeutic framing (JAK inhibitors, IL-1/IL-18 targeting) but lacks specific SAMHD1 or mechanistic pathway data.
DOI: 10.1002/acr.80127

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

IFI16/204 Promotes Dendritic Cell Activation and Anti-Hepatocellular Carcinoma Efficacy via the STING-TBK1-IRF3 Signalling Pathway. (from Oncology/Hepatology (tumor immunology))
Zhang Long; He Wenjing; Zhang Hanyuan; Zhang Xuzhi; Wang Hanyu — Immunology 2026
Score: 4/10 | Pathways: cGAS-STING, other

This paper demonstrates STING-TBK1-IRF3 signaling driving IFN-I-related dendritic cell activation, a downstream node in the BLUE pathway, but is focused on anti-tumor immunity in HCC rather than SAMHD1 biology, mitochondrial dysfunction, or the interferonopathy syndrome described.
DOI: 10.1111/imm.70152

Imaging Findings of Pediatric Rheumatic Disorders: JIA in the PRINTO Era and Autoimmune Interferonopathies. (from Pediatric radiology/rheumatology)
Y. Tsujioka; Yoshitake Yamada; Gen Nishimura; Tatsuo Kono; Masahiro Jinzaki — Pediatrics international : official journal of the Japan Pediatric Society 2026
Score: 3/10 | Pathways: JAK-STAT, AGS-spectrum, clinical-phenotype

This is a general pediatric rheumatology imaging review that mentions interferonopathies as a conceptual framework but provides no mechanistic or SAMHD1-specific data relevant to the disease profile.
DOI: 10.1111/ped.70487

CRISPR-Based Genome Editing in Contemporary Clinical Medicine: Therapeutic Translation, Global Challenges and the Future of Precision Medicine (from genomic medicine/regulatory policy)
Gabriel Alejandro Ortega Moreno; Gerardo Amaya Villagran; Andrés Mauricio Umaña * — International Science Journal 2026
Score: 3/10* | Pathways: gene-therapy-delivery, prime-editing

General CRISPR clinical translation review with no mention of SAMHD1 or related interferon/mitochondrial pathways, only tangentially relevant as background on gene editing platforms that could theoretically correct SAMHD1 variants.
DOI: 10.64784/277

Pathway Coverage This Week

  • treatment-target: 6 papers
  • cGAS-STING: 5 papers
  • clinical-phenotype: 3 papers
  • NLRP3: 3 papers
  • JAK-STAT: 3 papers
  • AGS-spectrum: 3 papers
  • gene-therapy-delivery: 2 papers
  • mTOR-lysosomal: 1 papers
  • urate-NLRP3: 1 papers
  • NF-kB-NLRP3-priming: 1 papers
  • other: 1 papers
  • prime-editing: 1 papers